Seattle Genetics Company Profile

Aggregated data from the web about Seattle Genetics

Company Name	Seattle Genetics
Website	https://www.seagen.com
Snippet	In itfor innovation. As a pioneer in antibody-drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. We’re committed to discovering safe and effective solutions to challenging clinical needs. Today, our research efforts are dedicated to advancing a pipeline of innovative therapies for solid tumors ...
Type	Public
Founded	1997
Revenue	2.176 Billion(2020)[2]
Website	seagen.com
Formerly	Seattle Genetics, Inc.(1997–2020)
Industry	Biotechnology, pharmaceutical
Products	Brentuximab vedotin and other antibody-drug conjugates
Traded as	Nasdaq: SGEN, NASDAQ-100 component
Key people	Clay B. Siegall Ph.D, (Chairman, President & CEO)[1], Todd E. Simpson, (CFO), Jean Liu, (Executive Vice President Legal Affairs, General Counsel, Corporate Secretary), Jonathan Drachman M.D., (Chief Medical Officer and Executive Vice President of R&D), Vaughn Himes, (Executive Vice President) Technical Operations and Process Sciences, Charles Romp, (Senior Vice President) Sales, Felix Baker, Lead Independent Director, Pinkston Peggy, Senior Director Corporate Communications
Headquarters	Bothell, Washington, U.S.
Number of employees	2700 (2021)

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.